Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > NGENF NERVGEN PHARMA CORP > Main Composition
NGENF NERVGEN PHARMA CORP
1.360
-0.034-2.44%
All
YOY
Do not show
Business

No Data

Region

No Data

Company Overview More
NervGen Pharma Corp. operates as a regenerative medicine company engaged in the discovery, development, and commercialization of therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. Its lead product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI). It has a licensing agreement with Case Western Reserve University in Cleveland, Ohio to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was founded by Brian J. McAlister and William Joseph Radvakon January 19, 2017 and is headquartered in Vancouver, Canada.
CEO: Mr. Paul Brennan
Market: Pink Market
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist